Multiple CD40 agonists have been investigated in clinical trials for pancreatic cancer, as recently reviewed by McVey et al.40These agonists can be broadly categorized based on their requirement for concurrent interaction with Fc gamma receptors (FcγR): some are FcγR-conditional (e.g., sotigalimab and mitazalimab), while others are non-conditional (e.g., selicrelimab and CDX-1140).41 Here, FCGR2A is linked to familial pancreatic carcinoma.